U.S. Market for Dental Lasers, New Report Launched

In 2013, the total U.S. market for dental laser systems was valued at $72.5 million. This market will beprimarily driven by the soft tissue diode laser market segment.

The dental laser device market is divided into three main segments. First is the soft tissue dental laser market, which includes diode laser systems, CO2 laser systems and Nd:YAG laser systems. Second is the all tissue dental laser market, which includes Er:YAG laser systems and Er,Cr:YSGG laser systems. Last is the dental welding laser market, which includes both benchtop and standalone dental cameras. Positive growth will be exhibited by all segments over the forecast period; however, overall market growth will be driven primarily by growth of the soft tissue laser segment as a result of the increasing market penetration of diode lasers.

Scope: This report pertains to a forecast period of 10 years (2010 – 2020) for the U.S.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Market Overview by Segment
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included:

• Soft Tissue Dental  Laser Market
• All Tissue Dental  Laser Market
• Dental Welding Laser Market

Reasons To Buy:

This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.

Spanning over 128 pages, “U.S. Market for Dental Lasers” report provides information on Research Methodology, U.S. Dental Laser Market Overview, Soft Tissue Dental Laser Market, All Tissue Dental Laser Market, Dental Welding Laser Market, Abbreviations. In This report cover 32 Companies- LNA Laser, Z-Tech Advanced Technologies, LightScalpel, Biolase, Lutronic, Sirona, AMD Lasers, Millennium Dental Technologies, Ivoclar Vivadent, Zila, Fotona, DEKA Laser etc.

For more information visit : http://www.marketresearchreports.com/idata-research/us-market-dental-lasers

Find all Medical Devices Reports under a single page.

High demand in U.S. video, high-tech and integrated operating room devices market, finds new report

In 2013, the U.S. market for video, high-tech and integrated OR equipment exceeded $1.8 billion.

The video, high-tech and integrated operating room equipment market includes integrated OR components, camera systems, image capture devices, displays, PACS monitors, light sources, medical printers, headlights, lighting, booms, tables, insufflation devices and surgical microscopes. High demand for OR integration will be the primary driver for all markets directly correlated, such as surgical monitors, image capture and recording devices, PACS monitors and surgical cameras.

Scope: This report pertains to a forecast period of 10 years (2010– 2020) for the U.S.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Market Overview by Segment
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included:

• Integrated Operating Room (OR) Market
• Surgical Camera System Market
• Image Capture and Recording Device Market
• Surgical Display and PACs Monitor Market
• Medical Printer Market
• Surgical Light Source Market
• Surgical Headlight Market
• Surgical Lighting Market
• Surgical Boom Market
• Surgical Table Market
• Insufflation Device Market
• Surgical Microscope Market

Reasons To Buy:

This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “ground up” approach, which includes primary and secondary research methods.

Spanning over 294 pages, “U.S. Video, High-Tech and Integrated Operating Room Market” report provides information on Research Methodology, U.S. Video, High-Tech And Integrated Or Equipment Market, Integrated Operating Room Market, Surgical Camera System Market, Digital Image Capture And Recording Device Market, Surgical Display And Pacs Monitor Markets, Medical Printer Market, Surgical Light Source Market, Surgical Headlight Market, Surgical Lighting Market, Surgical Boom Market, Surgery Table Market, Surgical Microscope Market, Insufflation Device Market, Abbreviations. In This report cover 62 Companies. SONY Medical, Olympus, MAQUET, Skytron, Berchtold, NDS Surgical Imaging, Leica Microsystems, Arthrex, Orthopedic Systems Inc, Integra Lifesciences, ConMed, Barco, Smith & Nephew, Sunoptic Technologies, Stryker, Karl Storz, STERIS, Carl Zeiss, Allen Medical Systems, Baxter Healthcare etc.

For more information visit : http://www.marketresearchreports.com/idata-research/us-video-high-tech-and-integrated-operating-room-market

Find all Pharma and Healthcare under a single page.

By 2020, the U.S. market for peripheral vascular devices will be worth over $6 billion

The peripheral vascular device market includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion devices, stent grafts, surgical grafts, arteriovenous (AV) access thrombectomy devices, inferior vena cava filters, catheters, guidewires, introducer sheaths, vascular closure devices and transcatheter embolization devices. These devices can be used for treating either coronary arterial or peripheral arterial disease (PAD), but only those devices used for peripheral procedures are included in this report. Older individuals and those who are obese have a higher risk of developing PAD. As result of a general increase in peripheral procedures and the development of new lower-limb treatments, the market for products such as stents and stent grafts will grow rapidly in the U.S. over the forecast period.

Peripheral artery disease (PAD) remains a significantly under treated condition in the U.S and PAD is the leading cause of leg amputation. These factors will continue to drive growth in the peripheral vascular device market. In particular, the peripheral stent market is projected to grow over the forecast period. However, intense competition has led to price erosion and market penetration has moderated this once high growth segment. The launch of new technologies, including drug-eluting stents, will generate marginal revenues and only one company has sought FDA approval. In contrast, significant investments and acquisitions have taken place in the efforts of bringing the first drug-eluting balloon to the market, with Medtronic and C. R. Bard in a tight race to gain approval.

Scope: This report pertains to a forecast period of 10 years (2010 – 2020) for the U.S.

Report Contents:

• Competitor Analysis
• Identified Strategic Opportunities
• Market Overview by Segment
• Trend Analysis by Segment
• Market Drivers & Limiters
• Mergers & Acquisitions
• Customer Feedback and Market Monitoring

Main Segments Included:

• Peripheral Vascular Stent Market
• PTA Balloon Catheter Market
• Atherectomy Device Market
• Chronic Total Occlusion (CTO) Device Market
• Embolic Protection Device Market
• Stent Graft Market
• Surgical Graft Market
• AV Access Thrombectomy Device Market
• Inferior Vena Cava Filter Market
• Diagnostic and Interventional Catheter Market
• Diagnostic and Interventional Guidewire Market
• Introducer Sheath Market
• Vascular Closure Device Market
• Transcatheter Embolization Device Market

Reasons To Buy:

This report analyzes and evaluates the current state of the market including existing and potential markets, product average selling prices, and unit volumes. The report also highlights the opportunities and potential hazards involved, and presents strategies for successfully navigating the market landscape. Furthermore, it seeks to identify the trends and technologies that will affect the future of each market segment and prepares an unbiased critical assessment of such market drivers and limiters based on our “bottom up” approach, which includes primary and secondary research methods.

Spanning over 356 pages, “U.S. Market for Peripheral Vascular Devices and Accessories” report provides information on Research Methodology, U.S. Peripheral Vascular Device Market Overview, Peripheral Vascular Stent Market, Pta Balloon Catheter Market, Atherectomy Device Market, Chronic Total Occlusion Device Market, Embolic Protection Device Market, Stent Graft Market, Surgical Graft Market, Arteriovenous (Av) Access Thrombectomy Device Market, Inferior Vena Cava Filter Market, Diagnostic And Interventional Catheter Market, Diagnostic And Interventional Guidewire Market, Introducer Sheath Market, Vascular Closure Device Market, Transcatheter Embolization Device Market, Abbreviations. In This report cover 38 Companies- C. R. Bard, Cordis, Abbott Laboratories, Terumo, Cook Medical, W. L. Gore, Boston Scientific, Covidien, Medtronic, St. Jude Medical, Cardiovascular Systems Inc, Atrium Medical, Endologix, Spectranetics,Pfizer, Argon Medical, AccessClosure, ALN International Inc., AngioDynamics, AngioScore etc.

For more information visit : http://www.marketresearchreports.com/idata-research/us-market-peripheral-vascular-devices-and-accessories

Find all Medical Devices Reports under a single page.

Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast - Global Analysis, New Report Launched

Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single “magic bullet” launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s disease drug market.

From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards, Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year 2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug Market.

New research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease Drug Market & Forecast - Global Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer’s Disease Drug Market.

Present & Pipeline Drugs Studied in this Report-

1. Namenda

2. Ebixa

3. Axura

4. Aricept

5. Nootropil

6. Exelon

7. Memary

8. Solanezumab

9. LuAe58054

This report contains 10 chapters.

(Chapter 1): Executive Summary

(Chapter 2): This Chapter is divided into 2 parts

A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018

B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market)

(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials

(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All the 9 Alzheimer’s drug mentioned above have been covered in this chapter.

(Chapter 5): This chapter talks about Alzheimer’s Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018.

(Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points:

A. Clinical Development Stage

B. Pipeline Drug Sales Performance

C. Recent Clinical Development

D. Different Companies Deal

E. Investment

(Chapter 7): This chapter speaks of Alzheimer’s Drugs Company deals in four areas

A. Strategic Alliances in Alzheimer’s Disease Drug Market

B. Licensing Agreement in Alzheimer’s Disease Drug Market

C. Collaboration Deal in Alzheimer’s Disease Drug Market

D. Merger & Acquisition in Alzheimer’s Disease Drug Market

(Chapter 8): This chapter studies Funding in Alzheimer’s Disease Drugs Research. We have covered 5 institutes which provides fund for the research.

A. National Institute of Health

B. Alzheimer's Association

C. Cure Alzheimer’s Fund

D. Alzheimer’s Drug Discovery Foundation

E. BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]

(Chapter 9): This chapter studies Growth Factors Driving the Alzheimer’s Disease Drug Market.

(Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer’s Disease Drug Market.

Data Sources

• This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research team of industry experts.
• Primary sources include industry surveys and telephone interviews with industry experts.
• Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

In addition to covering the Worldwide - Alzheimer’s Disease Drug Market Analysis, Failed Alzheimer’s Drugs, Worldwide - Alzheimer’s Disease Drug Market Share & Forecast, Worldwide – Alzheimer’s Drug Brands Market Performance, Pipeline Drugs Analysis in Alzheimer’s Disease Market, M&A, Licensing Agreement, Strategic Alliances & Collaboration Deals in Alzheimer’s Disease Drug Market, Funding in Alzheimer’s Disease Drugs Research, Key Drivers of Growth in Global Alzheimer’s Disease Drug Market, Key Challenges in the Global Alzheimer’s Disease Drug Market.

For more information visit : http://www.marketresearchreports.com/renub-research/alzheimer%E2%80%99s-pipeline-drugs-review-alzheimer%E2%80%99s-disease-drug-market-forecast-%E2%80%93-global

For other reports in Drug Discovery segment please visit: http://www.marketresearchreports.com/drug-discovery

MarketResearchReports.com: Influence of Antibody Attributes on Clinical Success - A Technology and Coporate Benchmark Analysis New Report Launched

How do antibody characteristics impact clinical success?

The analytical report ‘Influence of Antibody Attributes on Clinical Success - A Technology and Coporate Benchmark Analysis’ evaluates the impact of a number of antibody attributes on the success rate of antibodies in clinical development. Among the antibody attributes studied  in this investigation are antibody generation technology, animal species of the parental antibody, antibody format, immunoglobulin class and isotype, target, and therapeutic area. Information from more than 500 naked recombinant monoclonal antibodies was used for this research. Antibodies which failed in clinical development were further analyzed for the reason of failure and phase in which they were discontinued. Biotech and pharmaceutical companies with a significant R&D portfolio of therapeutic antibodies were benchmarked for their antibody success rate in development and the underlying antibody attributes contributing to success.

Specific antibody attributes evaluated for their influence on success in clinical development in this research study are:

• In vitro antibody generation technologies: display technologies from CAT, Dyax, Morphosys, BioInvent, Domantis, Genentech, others;
• In vivo antibody generation technologies: chimeric, primatized, nanobodies, deimmunized, human engineered, humaneered, humanized, XenoMouse, HuMab mouse, KM mouse, VelocImmune mouse, human B-cell derived;
• Animal species of parental wild-type antibody: mouse, rat, rabbit, hamster, cynomolgus monkey, camelid;
• Target;
• Immunoglobulin (Ig) class;
• IgG isotype;

Therapeutic area of lead indication.

When discovering a new monoclonal antibody, researchers have a number of choices to make regarding antibody generation technologies as well as antibody format and immunoglobulin isotpye among other attributes. One of the basic controversies in selecting the antibody generation technolgoy is the question whether antibodies generated in vitro by display technologies are really equivalent to those generated in vivo by a competent immune system.

Typical questions in antibody R&D are:

• When selecting an in vivo system for antibody generation, are conventional in vivo systems with an animal immune system and subsequent chimerization or humanization creating the same as „modern“ transgenic animals?
• Are full length antibodies more successful than modern engineered nanobodies, scFv molecules or even domain antibodies?
• Do companies have different success rates in their antibody development portfolio?
• And, if yes, are they using different technologies than their peers which could explain the difference?
• Is there a different success rate of antibodies against the same target based on generation technologies or other attributes?
• Are there therapeutic areas with higher likelihood of successful development of antibodies than others?
• What are the main reasons for antibody failure in clinical development?
• In which phase do antibodies typically fail?

This analytical report will give you answers for many of these questions. The results of the analysis show-

•  whether and how antibody generation technologies differently impact clinical success;
• why and when antibodies fail;
• how target selection influences clinical success;
• if antibody format, class and isotype is relevant for development success;
• the antibody success rate of therapeutic areas;
• which companies are the most successful and which antibody attributes they prefer.

Spanning over 88 pages and 45 tables, “Influence of Antibody Attributes on Clinical Success - A Technology and Coporate Benchmark Analysi” report provides an overview antibody technologies and attrition rates industry analysis 2013.

For more information visit : http://www.marketresearchreports.com/la-merie-publishing/influence-antibody-attributes-clinical-success-%E2%80%93-technology-and-coporate

Find all Pharmaceuticals and Healthcare Reports under a single page.

MarketResearchReports.com: Global hospital cardiac patient monitoring devices market to reach $5.3 billion by 2019 Finds New Report

The report has 230 pages, 102 tables and figures. Whereas cardiac monitor units were initially used in newly created critical care units, now many patients with primary disease conditions other than cardiac disease also have complications that affect the heart and therefor need monitoring in other parts of the hospital.

The hospital cardiac patient monitoring industry is evolving rapidly and is becoming increasingly competitive as more parameters are monitored and integration with the electronic patient record occurs. This is the basis on which vendor share shifts, with Philips gaining share in recent years. Companies with substantial resources are poised to enter the market, probably through acquisition. Vendors are poised to face increased competition even as market consolidation occurs.

Shortness of breath is a common symptom of cardiac disease. It is frequently misdiagnosed as a respiratory symptom or ignored by patients and is not even considered a symptom. Hospital cardiac patient monitoring can detect arrhythmias and get people to treatment faster before it is too late to correct heart failure.

Early detection of a problem in the hospital and consequent treatment is essential. Hospital cardiac patient monitoring technology is a vital aid in providing that treatment. Hospitals and clinicians have increased access to devices in every department of the hospital and during transport as insurers realize the value of detecting and treating cardiac symptoms as they occur, rather than waiting until the patient condition has deteriorated. .

Cardiac patient monitoring is evolving as systems become smaller and offer more functionality. Cardiac patient monitoring market driving forces still relate to reimbursement by CMS and private insurance carriers in the US and by nationalized systems in other places. The principal competitive factors that impact the success of cardiac monitoring solutions include the parameters discussed in the market research study:

According to lead author who have prepared the Hospital Patient Multi -Parameter Monitors market research study, "Hospital cardiac patient monitoring technology companies are struggling to achieve a focus on health delivery and well-being initiatives. Vendors strive for a balanced portfolio of businesses that can attain global leadership positions. Vendors seek to deliver performance above benchmark levels. Challenges are influencing hospital cardiac patient monitoring business activities"

When chronic disease conditions are treated early on when there is an early change in patient condition an early intervention can make a difference. It is even better to treat patients in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on.

Global hospital cardiac patient monitoring devices market at $3.8 billion in 2012 is forecast to reach at $5.3 billion by 2019 at a growth rate of 5.5% during the analysis period. Growth continues as market penetration into all areas of the hospital expands. The installed base continues to grow as replacement of units is stretched to 12 years and beyond.

For more information visit : http://www.marketresearchreports.com/wintergreen-research/hospital-patient-multi-parameter-monitors-market-shares-strategies-and

Find all Pharmaceuticals and Healthcare Reports under a single page.

MarketResearchReports.com: Telemedicine push to talk PTT markets to reach $4.4 billion by 2019 Reveals New Report

The report has 791 pages, 278 tables and figures. Worldwide markets are poised to achieve significant growth as the push to talk is used inside telemedicine systems and m-health initiatives as a way to implement ruggedized handset communications for all clinicians.

Worldwide Tele-medicine and M-health PTT push to talk device market driving forces relate to an overall trend toward clinical reimbursement addressing mobile health initiative for chronic conditions. This trend promises to become prevalent as people learn how to keep themselves healthier. Healthy behaviors such as exercise, good diet and stress management have the potential to reverse aging on a molecular level and partly restore the vitality of a person's cells.

Healthy lifestyle choices can increase the length of DNA sequences found at the end of a person's chromosomes. This shift toward wellness has stimulated the need for better communication between clinicians and patients. New sensor technology creates the opportunity for monitoring and for alerts to be send to and from at risk people who are exercising.

PTT telemedicine markets are poised to achieve significant growth as the existing telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health.

There is a convergence of telemedicine and m-health as the patient uses push to talk devices in telemonitoring situations where the sensor data is transmitted to a facility, encouraging the patient to become more responsible for their own care delivery and their own health. Push to talk devices are more rugged than ordinary smart phones and are used in transport situations inside the hospital and in ambulances.

Healthcare patient, physician, and facility decision support markets are forecast based n the broad availability of smartphones combined with the IBM Watson technology that Watson offers Interactive Care Insights for Oncology. The cognitive systems use insights gleaned from the deep experience of Memorial Sloan-Kettering clinicians. Watson is positioned to permit clinicians to provide individualized treatment.

According to Susan Eustis, lead author of the Publisher Research team that prepared the telemedicine market research study, "Telemedicine push to talk PTT markets are evolving as smart phone devices find more uses during patient transport. During emergency transport, sensors can provide monitoring that has not previously been available. Differential diagnostic tools support differential tele-medical treatment. The decision process take into account clinical findings form the home monitoring devices and from symptoms verbally communicated in a clinical services implementation."

Both tele-medicine and m-health contribute to healthcare delivery in the home. M-health will surely be delivered over the smart phone. Tele-medicine is evolving toward smart phone device delivery as well. 

The cost of tele-medicine for the US veterans administration is $1,600 per patient per annum. This is substantially less than other NIC programs and nursing home care which can easily run to $100,000 per annum. VHA's experience is that an enterprise-wide home tele-medicine implementation is an appropriate and cost-effective way of managing chronic care patients in both urban and rural settings.

Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on.

Telemedicine delivered on proprietary devices is becoming obsolete. Kyocera is the market leader in push to talk phones for telemedicine. The Honeywell / Samsung strategic alliance represents the smart phone model that works. Telemedicine market analysis indicates that the price points are way below device costs and that companies are seeking to gain market share by working with clients.

Telemedicine push to talk PTT dedicated device and software markets at $214 million in 2012 are anticipated to reach $4.4 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the leveraging of 8.5 billion smart phones and 5 billion connected tablet devices all over the world.

For more information visit : http://www.marketresearchreports.com/wintergreen-research/push-talk-telemedicine-and-m-health-convergence-market-shares-strategies-and

Find all Pharmaceuticals and Healthcare Reports under a single page.